Clinical data | |
---|---|
Trade names | Stelazine, Eskazinyl, Eskazine, Jatroneural, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682121 |
Pregnancy category |
|
Routes of administration | By mouth, IM |
Drug class | Typical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 10–20 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.003.837 |
Chemical and physical data | |
Formula | C21H24F3N3S |
Molar mass | 407.50 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia.[3] It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines.[3] It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.[4]